The CD13 inhibitor ubenimex (bestatin) reduces stemness (475, 585), while NGR-LDP-AE—a fusion protein combining a CD13-targeting peptide with lidamycin—shows significant anti-tumor effects by targeting CD13+ Liver-CSCs and inhibiting angiogenesis (586). This evidence concerns the gene ANPEP and neoplasm.